1,186 results on '"Baum R"'
Search Results
2. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
3. PCR201 Estimating the Respiratory Syncytial Virus (RSV) Health Utility Values for Older Adults and Their Caregivers in the Japanese Population: A Time Trade-Off (TTO) Study
4. Improving predictive power of physically based rainfall-induced shallow landslide models: a probabilistic approach
5. Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors
6. PSMA radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry
7. Long-Term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients with Refractory Meningioma
8. SSTR-Antagonist [68Ga]Ga-DATA5m-LM4 zu Bildgebung von gut differenzierten neuroendokrinen Tumoren: von der Produktion zu ersten klinischen Ergebnissen
9. Von der vollautomatischen Synthese von [68Ga]Ga-DATA5m.SA.FAPi zu ersten klinischen Untersuchungen
10. Radiolabeling of 3BP-3940 with 68Ga, 90Y, 177Lu and 225Ac for imaging and Peptide Targeted Radiotherapy (PTRT)
11. Long-Term Tolerability, Efficacy and Survival of Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors of Unknown Primary (CUP-NETs)
12. FAP-Peptidvermittelte Radiorezeptortherapie (PTRT) bei soliden Tumoren: erste klinische Erfahrungen mit dem 177Lu-, 225Ac- oder 90Y-markierten Peptid 3BP-3940
13. First-in-human Study of an Optimized, Kit-type, SSTR Antagonist 68Ga-DATA5m-LM4 in Patients with Metastatic Neuroendocrine Tumors
14. Fibroblast Activating Protein (FAP)-Targeted Radiopeptide Therapy using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results
15. Einfluss der PSMA-Radioligandentherapie (PRLT) auf die Immunogenität einer Impfung gegen SARS-CoV-2 - eine retrospektive einarmige Kohortenstudie bei Patienten mit metastasierten Prostatakarzinomen
16. HTA163 Development of SF-6Dv2 Health Utility Weights in the United States
17. HTA163 Development of SF-6Dv2 Health Utility Weights in the United States
18. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry
19. Klinische Indikationen
20. Receptor PET/CT Imaging of Neuroendocrine Tumors
21. Radioimmunotherapy
22. Effect of antecedent-hydrological conditions on rainfall triggering of debris flows in ash-fall pyroclastic mantled slopes of Campania (southern Italy)
23. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors
24. The role of image fusion in diagnostic imaging for stereotactic neurosurgery and radiosurgery/stereotactic radiotherapy
25. Supporting information retrieval in times of a pandemic - a library's perspective
26. Meta‐analysis of individual‐patient data from EVAR‐1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years
27. Ergebnisse in den Neurologischen Kliniken
28. Clinical Indications
29. Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status
30. Simulated effect of topography and soil properties on hydrologic response and landslide potential under variable rainfall conditions in the Oregon Coast Range, USA
31. Positronenemissionstomographie des Herzens
32. POSC381 Derivation of Interpretation Thresholds for the SF-36V2® Health Survey (SF-36V2) in Rheumatoid Arthritis
33. POSA378 Derivation of Interpretation Thresholds for the Rheumatoid Arthritis Symptoms and Impact Questionnaire (RASIQ) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE) Scale
34. The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm
35. Möglichkeiten und Grenzen der Immunszintigraphie in der Diagnostik des Ovarialkarzinoms
36. Onkologie I: Klinik
37. Deterministic estimation of hydrological thresholds for shallow landslide initiation and slope stability models: case study from the Somma-Vesuvius area of southern Italy
38. Novel Monoclonal Antibody 138H11 Against Human γ-Glutamyl-Transferase: Classification, Histogenesis and Immunoscintigraphy of Renal Tumors
39. 18-FDG-PET in Diagnosestellung und Verlauf bei Patienten mit Dermatomyositis
40. Chemoembolization of Hepatic Tumors with Degradable Starch Microspheres
41. Six Years of Experience with Local Chemotherapy of the Liver
42. O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate
43. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
44. Die Zukunft des Deutschen MeSH: Vom Übersetzungsprozess zum Terminologie-Service
45. Neuroendokrine Neoplasien des gastroenteropankreatischen Systems: Pathologie und Klassifikation
46. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
47. PCR63 A Time Trade-Off Study to Estimate Respiratory Syncytial Virus (RSV) Related Utility Values for Older Adults (OA) in the United States (US)
48. Der Einfluss vorheriger Therapien auf das Gesamtüberleben bei mCRPC-Patienten, die eine Lu-PSMA-617-Therapie erhalten. Eine retrospektive multizentrische Studie von WARMTH
49. The future of German MeSH: a new semi-automatic translation process and new services for search and annotation
50. Korrelation histologischer und nuklearmedizinischer Befunde der Tumorregression in behandelten bösartigen Lungentumoren
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.